Why Testing for 7-Hydroxymitragynine Matters: Understanding the Emerging Risk Behind Kratom Products
Author: Jordan Kelsey
Kratom has been circulating for years in the wellness and supplement space, often marketed as an herbal energy booster or natural pain reliever. But recently, it has surged back into national headlines—especially as the Beshear administration announced movement toward classifying 7‑hydroxymitragynine (7-HMG) as a Schedule I controlled substance in Kentucky This reflects growing concern across public-health agencies about the safety, abuse-potential, and rapid evolution of kratom-derived products.
At Gravity Diagnostics, we closely follow these trends because they directly affect patient care, provider safety, and community health. As one of the few laboratories offering LC/MS confirmation testing for both mitragynine and 7-HMG, we have unique visibility into how these substances show up in clinical toxicology.
This post explains what kratom is, why 7-HMG has become the focus of regulation, and why testing for both compounds—not just mitragynine—is essential for clinicians, addiction treatment providers, and monitoring programs.
What Is Kratom?
Kratom (Mitragyna speciosa) is a plant native to Southeast Asia. Its leaves contain many alkaloids, but two are most relevant in drug-testing: mitragynine (the primary and most abundant alkaloid) and 7-HMG (a more potent alkaloid/metabolite responsible for much of kratom’s opioid-like effects).
Although kratom itself is not currently classified as a narcotic under federal law, regulatory pressure is increasing. Several states—including Kentucky—are targeting 7-HMG specifically because of its potency and growing presence in misuse cases.
Why the Public Should Care
Many consumers view kratom as a harmless natural supplement, but it carries well-documented risks. Its alkaloids act on the μ-opioid receptor, which can lead to dependence, withdrawal, and drug-seeking behavior. Kratom products also interact dangerously with other substances, increasing overdose risk, and the industry has no consistent manufacturing oversight—allowing extremely potent extracts to enter the market with no safety regulation.
Most importantly, the market is shifting away from traditional kratom preparations toward concentrated products and pure 7-HMG materials. These newer formulations can be far stronger than natural kratom and may contain little or no mitragynine, making them invisible to tests that only target the parent compound.
Why 7-Hydroxymitragynine Testing Is Critical
Potency
While both mitragynine and 7-HMG bind to the μ-opioid receptor, 7-HMG is far more potent and more likely to produce euphoric and reinforcing opioid-like effects. One report notes that 7-HMG “is only a minor kratom constituent, but it is much more potent than mitragynine.” Another source reports 7-HMG is “about 10 times more potent than mitragynine at the receptor with an EC₅₀ = 35 nM in vitro (versus ~339 nM for mitragynine).” Also, in Texas health-alerts, 7-HMG showed “up to 13 times the potency of morphine” in some studies.
This higher potency increases the risk of misuse, dependence, and severe withdrawal.
Market Shift to Pure 7-HMG Products
Historically, kratom use was linked to raw plant material. Today, gas stations, vape stores, and head shops increasingly carry synthesized or semi-synthetic 7-HMG products marketed as “kratom extracts” or “legal highs.” These products can contain 7-HMG as the only active compound, which means patients using them might have no detectable mitragynine at all. Any toxicology panel that excludes 7-HMG will completely miss this rising class of products.
Detection Window & Blind Spots
Testing only for mitragynine shortens the detection window. In natural kratom use, mitragynine is the parent compound and 7-HMG appears in smaller amounts as a metabolite. If only mitragynine is tested, late detection is missed and any use of stand-alone 7-HMG products is undetectable. For example, one human pharmacokinetic study found the half-life of 7-HMG to be shorter (~4.7 hours single dose) compared to mitragynine (~43.4 hours).
This is a major issue for addiction treatment programs, pain management monitoring, drug courts, and behavioral health providers—missing 7-HMG use can lead to incorrect assumptions about compliance or abstinence.
What Gravity Diagnostics Tests, and Why It Matters
Gravity Diagnostics offers LC/MS confirmation testing for both mitragynine and 7-hydroxymitragynine, which allows providers to detect natural kratom use, high-potency extracts, and synthetic 7-HMG-only products. LC/MS technology offers greater sensitivity and specificity than traditional immunoassays, which often fail to detect kratom alkaloids due to their unique chemical structures.
By testing for both compounds, we capture the full spectrum of exposures. Our testing also gives us insight into emerging trends, including increasing cases in which 7-HMG is present without mitragynine—an indicator that pure 7-HMG products are entering communities.
Why Competitor Panels Fall Short
Many toxicology labs still test for mitragynine only or omit kratom-alkaloid confirmation altogether. Panels that exclude 7-HMG create significant blind spots, including undetected use of 7-HMG-only products and false assumptions regarding abstinence or compliance. Given how quickly kratom derivatives are changing, a mitragynine-only panel is no longer clinically sufficient.
Final Takeaway
Kratom is evolving quickly—and so is the risk associated with its high-potency derivatives. As Kentucky and other states move toward regulating 7-HMG, now is the time for clinicians and monitoring programs to evaluate whether their toxicology panels are keeping pace. Testing only mitragynine is no longer enough.
Gravity Diagnostics provides comprehensive LC/MS testing capable of detecting natural kratom use, concentrated extracts, stand-alone 7-HMG products, and patterns of misuse or relapse. This level of accuracy helps providers make informed, evidence-based decisions that protect both patients and the broader community.
References
- Behnood-Rod A, et al. “Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine.” PMC (2020). PMC
- Kruegel AC, et al. “7-Hydroxymitragynine Is an Active Metabolite of Mitragynine… via the µ-opioid receptor.” PMC (2019). PMC
- “Mitragynine binds with much lower affinity… 7-hydroxymitragynine is about 10 times more potent…” University of Florida Kratom resources. csp.pharmacy.ufl.edu
- “Serious illnesses associated with 7-OH use.” Texas DSHS (2025). Texas Health Services
- “Beshear administration moves to ban kratom by-product 7-OH.” WKYT, Nov 9 2025. https://www.wkyt.com
- “State health cabinet to ban sale and possession of ‘dangerous’ kratom derivative.” Kentucky Lantern, Nov 6 2025. Kentucky Lantern
- Chemical composition and biological effects of kratom: “Kratom produces more than 40 structurally related alkaloids…” Todd DA, et al., Scientific Reports (2020). Nature